Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (Il)-10 and IL-1RN levels

Stem Cells Translational Medicine

Volumn 2, Issue 11, 2013, Pages 884-895

  Bustos, Martha L ^a,b   Huleihel, Luai ^a,b,c   Meyer, Ernest M ^d   Donnenberg, Albert D ^d,e   Donnenberg, Vera S ^e,f   Sciurba, Joseph D ^a,b   Mroz, Lyle ^a,b   McVerry, Bryan J ^a   Ellis, Bryon M ^a   Kaminski, Naftali ^a,b   Rojas, Mauricio ^a,b,e  

^a Allergy   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adult stem cells; Bone marrow stromal cells; Lung; Mesenchymal stem cells

Indexed keywords

CYTOKINE; GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL ISOLATION; CELL MANIPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATORY CELL; LUNG EDEMA; LUNG INJURY; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALIA; MURINAE; MUS;

EID: 84886455453     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0033     Document Type: Article

References (79)

1. Goodman RB, Pugin J, Lee JS et al. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev 2003;14: 523-535.
2. Ranieri VM, Rubenfeld GD, Thompson BT et al. Acute respiratory distress syndrome: The Berlin Definition. JAMA 2012; 307:2526-2533.
3. Saguil A, Fargo M. Acute respiratory distress syndrome: Diagnosis and management. Am Fam Physician 85:352-358.
4. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-1349.
5. Pittet JF, Mackersie RC, Martin TR et al. Biological markers of acute lung injury: Prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997;155:1187-1205.
6. Matthay MA, Zemans RL. The acute respiratory distress syndrome: Pathogenesis and treatment. Annu Rev Pathol 2011;6: 147-163.
7. Di Paola R, Talero E, Galuppo M et al. Adrenomedullin in inflammatory process associated with experimental pulmonary fibrosis. Respiratory Research 2011;12:41.
8. Hayes M, Curley G, Ansari B et al. Clinical review: Stem cell therapies for acute lung injury/acute respiratory distress syndrome: Hope or hype? Crit Care 2012;16:205.
9. Dhaliwal K, Scholefield E, Ferenbach D et al. Monocytes control second-phase neutrophil emigration in established lipopolysaccha-induced murine lung injury. Am J Respir Crit Care Med 2012;186:514-524.
10. Levitt JE, Matthay MA. Clinical review: Early treatment of acute lung injury: Paradigm shift toward prevention and treatment prior to respiratory failure. Crit Care 2012; 16:223.
11. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301-1308.
12. De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A et al. Immunosuppressive properties of mesenchymal stem cells: Advances and applications. Curr Mol Med 2012; 12:574-591.
13. Gregory CA, Ylostalo J, Prockop DJ. Adult bone marrow stem/progenitor cells (MSCs) are preconditioned by microenvironmental "niches" in culture: A two-stage hypothesis for regulation of MSC fate. Sci STKE 2005;2005: pe37.
14. Gotts JE, Matthay MA. Mesenchymal stem cells and acute lung injury. Crit Care Clin 2011;27:719-733.
15. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822.
16. Majumdar MK, Keane-Moore M, Buyaner D et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 2003;10: 228-241.
17. Tse WT, Pendleton JD, Beyer WM et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 2003;75: 389-397.
18. Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 CD25highFOXP3 regulatory T cells. STEM CELLS 2008;26:212-222.
19. Shi M, Liu ZW, Wang FS. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol 2011;164:1-8.
20. Lee JW, Fang X, Krasnodembskaya A et al. Concise review: Mesenchymal stem cells for acute lung injury: Role of paracrine soluble factors. STEM CELLS 2011;29:913-919.
21. Yi T, Song SU. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res 2012;35:213-221.
22. Batten P, Sarathchandra P, Antoniw JW et al. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: Relevance to tissue engineering human heart valves. Tissue Eng 2006;12:2263-2273.
23. Rasmusson I, Ringden O, Sundberg B et al. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005;305:33-41.
24. Del Sorbo L, Goffi A, Ranieri VM. Mechanical ventilation during acute lung injury: Current recommendations and new concepts. Presse Med 2011;40:e569-e583.
25. Ylostalo JH, Bartosh TJ, Coble K et al. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. STEM CELLS 2012;30:2283-2296.
26. Ortiz LA, Dutreil M, Fattman C et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007;104:11002-11007.
27. Fridman O, Porcile R, Morales AV et al. Association of methylenetetrahydrofolate reductase gene 677C T polymorphism with hypertension in older women in a population of Buenos Aires City. Clin Exp Hypertens 2013;35: 159-166.
28. Gupta N, Su X, Popov B et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007;179: 1855-1863.
29. Mao M, Wang SN, Lv XJ et al. Intravenous delivery of bone marrow-derived endothelial progenitor cells improves survival and attenuates lipopolysaccharide-induced lung injury in rats. Shock 2010;34:196-204.
30. Sun J, Han ZB, Liao W et al. Intrapulmonary delivery of human umbilical cord mesenchymal stem cells attenuates acute lung injury by expanding CD4 CD25 Forkhead Boxp3 (FOXP3) regulatory T cells and balancing antiand pro-inflammatory factors. Cell Physiol Biochem 2011;27:587-596.
31. Gregory CA, Prockop DJ, Spees JL. Nonhematopoietic bone marrow stem cells: Molecular control of expansion and differentiation. Exp Cell Res 2005;306:330-335.
32. Li W, Ren G, Huang Y et al. Mesenchymal stem cells: A double-edged sword in regulating immune responses. Cell Death Differ 2012;19: 1505-1513.
33. Xu J, Qu J, Cao L et al. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol 2008;214:472-481.
34. Yilmaz S, Inandiklioglu N, Yildizdas D et al. Mesenchymal stem cell: Does it work in an experimental model with acute respiratory distress syndrome? Stem Cell Rev 2013; 9:80-92.
35. Kim ES, Chang YS, Choi SJ et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli-induced acute lung injury in mice. Respir Res 2011;12:108.
36. Macmillan ML, Blazar BR, DeFor TE et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: Results of a phase I-II clinical trial. Bone Marrow Transplant 2009;43:447-454.
37. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579-1586.
38. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versushost disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363: 1439-1441.
39. Vojtassak J, Danisovic L, Kubes M et al. Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro Endocrinol Lett 2006;2(suppl 2):134-137.
40. Yun JH. Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis. Ann Intern Med 2011; 155:65; author reply 65-66.
41. Christopeit M, Schendel M, Foll J et al. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008;22:1062-1064.
42. Kharaziha P, Hellstrom PM, Noorinayer B et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: A phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21:1199-1205.
43. Sun L, Wang D, Liang J et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010;62:2467-2475.
44. Duijvestein M, Vos AC, Roelofs H et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: Results of a phase I study. Gut 2010;59:1662-1669.
45. Nauta AJ, Westerhuis G, Kruisselbrink AB et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006;108: 2114-2120.
46. Djouad F, Fritz V, Apparailly F et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005;52:1595-1603.
47. Miura Y, Kami M, Tsubokura M et al. Mesenchymal stem cells for acute graft-versus-host disease. Lancet 2008;372:715-716; author reply 716.
48. Nikitina VA, Osipova EY, Katosova LD et al. Study of genetic stability of human bone marrow multipotent mesenchymal stromal cells. Bull Exp Biol Med 2011;150:627-631.
49. Ben-David U, Mayshar Y, Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell 2011;9:97-102.
50. Jeong JO, Han JW, Kim JM et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res 2011;108:1340-1347.
51. Grigorian AS, Kruglyakov PV, Taminkina UA et al. Alterations of cytological and karyological profile of human mesenchymal stem cells during in vitro culturing. Bull Exp Biol Med 2010;150:125-130.
52. Rsland GV, Svendsen A, Torsvik A et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009;69:5331-5339.
53. Gorantla VS, Schneeberger S, Moore LR et al. Development and validation of a procedure to isolate viable bone marrow cells from the vertebrae of cadaveric organ donors for composite organ grafting. Cytotherapy 2012; 14:104-113.
54. Donnenberg AD, Gorantla VS, Schneeberger S et al. Clinical implementation of a procedure to prepare bone marrow cells from cadaveric vertebral bodies. Regen Med 2011;6: 701-706.
55. Gunn WG, Conley A, Deininger L et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: A potential role in the development of lytic bone disease and tumor progression in multiple myeloma. STEM CELLS 2006; 24:986-991.
56. Hung SC, Pochampally RR, Hsu SC et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2007;2:e416.
57. Zimmerlin L, Donnenberg VS, Pfeifer ME et al. Stromal vascular progenitors in adult human adipose tissue. Cytometry A 2010;77:22-30.
58. Zimmerlin L, Donnenberg VS, Donnenberg AD. Rare event detection and analysis in flow cytometry: Bone marrow mesenchymal stem cells, breast cancer stem/progenitor cells in malignant effusions, and pericytes in disaggregated adipose tissue. Methods Mol Biol 2011;699:251-273.
59. Donnenberg VS, Donnenberg AD, Zimmerlin L et al. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry B Clin Cytom 2010;78:287-301.
60. Hoffman RA, Wood JC. Characterization of flow cytometer instrument sensitivity. Current Protoc Cytom 2007;Chapter 1:Unit 1.20.
61. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408.
62. Iyer SS, Torres-Gonzalez E, Neujahr DC et al. Effect of bone marrow-derived mesenchymal stem cells on endotoxin-induced oxidation of plasma cysteine and glutathione in mice. Stem Cells Int 2010;2010:868076.
63. Rojas M, Parker RE, Thorn N et al. Infusion of freshly isolated autologous bone marrow derived nuclear cells prevents endotoxin-induced lung injury in an ex-vivo perfused swine model. Stem Cell Res Ther 2013; 4:26.
64. Horn P, Bork S, Wagner W. Standardized isolation of human mesenchymal stromal cells with red blood cell lysis. Methods Mol Biol 2011;698:23-35.
65. Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003;100:8407-8411.
66. Takaoka Y, Niwa S, Nagai H. Interleukin-1beta induces interleukin-6 production through the production of prostaglandin E(2) in human osteoblasts, MG-63 cells. J Biochem 1999;126:553-558.
67. Sharma SK, MacLean JA, Pinto C et al. The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury. Am J Respir Crit Care Med 1996;154:193-200.
68. Geiser T, Atabai K, Jarreau PH et al. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1beta-dependent mechanism. Am J Respir Crit Care Med 2001;163:1384-1388.
69. Ren G, Su J, Zhang L et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. STEM CELLS 2009;27:1954-1962.
70. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141-150.
71. Inoue G. Effect of interleukin-10 (IL-10) on experimental LPS-induced acute lung injury. J Infect Chemother 2000;6:51-60.
72. Danchuk S, Ylostalo JH, Hossain F et al. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6. Stem Cell Res Ther 2011;2:27.
73. Groh ME, Maitra B, Szekely E et al. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005;33:928-934.
74. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-4621.
75. Renner P, Eggenhofer E, Rosenauer A et al. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc 2009;41:2607-2611.
76. Romieu-Mourez R, Francois M, Boivin MN et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009;182:7963-7973.
77. Mestas J, Hughes CC. Of mice and not men: Differences between mouse and human immunology. J Immunol 2004;172: 2731-2738.
78. Reiser J, Zhang XY, Hemenway CS et al. Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther 2005;5:1571-1584.
79. Haniffa MA, Wang XN, Holtick U et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007;179: 1595-1604.